2bk3 › Citations

Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors.

Hubálek F, Binda C, Khalil A, Li M, Mattevi A, Castagnoli N, Edmondson DE
J Biol Chem 280 15761-6 (2005)
Related entries: 2bk4, 2bk5

Cited: 103 times
EuropePMC logo PMID: 15710600

Abstract

Several reversible inhibitors selective for human monoamine oxidase B (MAO B) that do not inhibit MAO A have been described in the literature. The following compounds: 8-(3-chlorostyryl)caffeine, 1,4-diphenyl-2-butene, and trans,trans-farnesol are shown to inhibit competitively human, horse, rat, and mouse MAO B with K(i) values in the low micromolar range but are without effect on either bovine or sheep MAO B or human MAO A. In contrast, the reversible competitive inhibitor isatin binds to all known MAO B and MAO A with similar affinities. Sequence alignments and the crystal structures of human MAO B in complex with 1,4-diphenyl-2-butene or with trans,trans-farnesol provide molecular insights into these specificities. These inhibitors span the substrate and entrance cavities with the side chain of Ile-199 rotated out of its normal conformation suggesting that Ile-199 is gating the substrate cavity. Ile-199 is conserved in all known MAO B sequences except bovine MAO B, which has Phe in this position (the sequence of sheep MAO B is unknown). Phe is conserved in the analogous position in MAO A sequences. The human MAO B I199F mutant protein of MAO B binds to isatin (K(i) = 3 microM) but not to the three inhibitors listed above. The crystal structure of this mutant demonstrates that the side chain of Phe-199 interferes with the binding of those compounds. This suggests that the Ile-199 "gate" is a determinant for the specificity of these MAO B inhibitors and provides a molecular basis for the development of MAO B-specific reversible inhibitors without interference with MAO A function in neurotransmitter metabolism.

Articles - 2bk3 mentioned but not cited (10)

  1. Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis. Badavath VN, Baysal İ, Ucar G, Sinha BN, Jayaprakash V. ACS Med Chem Lett 7 56-61 (2016)
  2. A theoretical study on predicted protein targets of apple polyphenols and possible mechanisms of chemoprevention in colorectal cancer. Scafuri B, Marabotti A, Carbone V, Minasi P, Dotolo S, Facchiano A. Sci Rep 6 32516 (2016)
  3. SAR and molecular mechanism studies of monoamine oxidase inhibition by selected chalcone analogs. Shalaby R, Petzer JP, Petzer A, Ashraf UM, Atari E, Alasmari F, Kumarasamy S, Sari Y, Khalil A. J Enzyme Inhib Med Chem 34 863-876 (2019)
  4. Computational Drug Target Screening through Protein Interaction Profiles. Vilar S, Quezada E, Uriarte E, Costanzi S, Borges F, Viña D, Hripcsak G. Sci Rep 6 36969 (2016)
  5. Binding of mycotoxins to proteins involved in neuronal plasticity: a combined in silico/wet investigation. Scafuri B, Varriale A, Facchiano A, D'Auria S, Raggi ME, Marabotti A. Sci Rep 7 15156 (2017)
  6. A Combined Network Pharmacology and Molecular Docking Approach to Investigate Candidate Active Components and Multitarget Mechanisms of Hemerocallis Flowers on Antidepressant Effect. Ma T, Sun Y, Jiang C, Xiong W, Yan T, Wu B, Jia Y. Evid Based Complement Alternat Med 2021 7127129 (2021)
  7. Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson's Disease. Duarte P, Michalska P, Crisman E, Cuadrado A, León R. Antioxidants (Basel) 11 247 (2022)
  8. A Bio-Indicator Pilot Study Screening Selected Heavy Metals in Female Hair, Nails, and Serum from Lifestyle Cosmetic, Canned Food, and Manufactured Drink Choices. Hamouda AF, Felemban S. Molecules 28 5582 (2023)
  9. Computational investigation of unsaturated ketone derivatives as MAO-B inhibitors by using QSAR, ADME/Tox, molecular docking, and molecular dynamics simulations. El Aissouq A, Bouachrine M, Ouammou A, Khalil F. Turk J Chem 46 687-703 (2022)
  10. Molecular docking analysis and dynamics simulation of salbutamol with the monoamine oxidase B (MAO-B) enzyme. Abdulhameed Odhar H, Fadhil Hashim A, Sami Humad S. Bioinformation 18 304-309 (2022)


Reviews citing this publication (14)

  1. The therapeutic potential of monoamine oxidase inhibitors. Youdim MB, Edmondson D, Tipton KF. Nat Rev Neurosci 7 295-309 (2006)
  2. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Edmondson DE, Binda C, Wang J, Upadhyay AK, Mattevi A. Biochemistry 48 4220-4230 (2009)
  3. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Edmondson DE, Binda C, Mattevi A. Arch Biochem Biophys 464 269-276 (2007)
  4. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Petzer JP, Castagnoli N, Schwarzschild MA, Chen JF, Van der Schyf CJ. Neurotherapeutics 6 141-151 (2009)
  5. MAO inhibitors and their wider applications: a patent review. Carradori S, Secci D, Petzer JP. Expert Opin Ther Pat 28 211-226 (2018)
  6. Focusing on new monoamine oxidase inhibitors. Bolasco A, Carradori S, Fioravanti R. Expert Opin Ther Pat 20 909-939 (2010)
  7. Kinetics, mechanism, and inhibition of monoamine oxidase. Ramsay RR, Albreht A. J Neural Transm (Vienna) 125 1659-1683 (2018)
  8. Monoamine oxidases in development. Wang CC, Billett E, Borchert A, Kuhn H, Ufer C. Cell Mol Life Sci 70 599-630 (2013)
  9. Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches. Hong R, Li X. Medchemcomm 10 10-25 (2019)
  10. Methylene blue and its analogues as antidepressant compounds. Delport A, Harvey BH, Petzer A, Petzer JP. Metab Brain Dis 32 1357-1382 (2017)
  11. Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development. Aljanabi R, Alsous L, Sabbah DA, Gul HI, Gul M, Bardaweel SK. Molecules 26 6019 (2021)
  12. Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches. Duarte P, Cuadrado A, León R. Handb Exp Pharmacol 264 229-259 (2021)
  13. Natural Products Inhibitors of Monoamine Oxidases-Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma. Chaurasiya ND, Leon F, Muhammad I, Tekwani BL. Molecules 27 4297 (2022)
  14. Structure-Based Design of Novel MAO-B Inhibitors: A Review. Mateev E, Georgieva M, Mateeva A, Zlatkov A, Ahmad S, Raza K, Azevedo V, Barh D. Molecules 28 4814 (2023)

Articles citing this publication (79)

  1. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. De Colibus L, Li M, Binda C, Lustig A, Edmondson DE, Mattevi A. Proc Natl Acad Sci U S A 102 12684-12689 (2005)
  2. Structures and Mechanism of the Monoamine Oxidase Family. Gaweska H, Fitzpatrick PF. Biomol Concepts 2 365-377 (2011)
  3. Potentiation of ligand binding through cooperative effects in monoamine oxidase B. Bonivento D, Milczek EM, McDonald GR, Binda C, Holt A, Edmondson DE, Mattevi A. J Biol Chem 285 36849-36856 (2010)
  4. Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Strydom B, Malan SF, Castagnoli N, Bergh JJ, Petzer JP. Bioorg Med Chem 18 1018-1028 (2010)
  5. A peroxidase-coupled continuous absorbance plate-reader assay for flavin monoamine oxidases, copper-containing amine oxidases and related enzymes. Holt A, Palcic MM. Nat Protoc 1 2498-2505 (2006)
  6. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Naoi M, Maruyama W. Expert Rev Neurother 9 1233-1250 (2009)
  7. New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. Gökhan-Kelekçi N, Koyunoğlu S, Yabanoğlu S, Yelekçi K, Ozgen O, Uçar G, Erol K, Kendi E, Yeşilada A. Bioorg Med Chem 17 675-689 (2009)
  8. The 'gating' residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition. Milczek EM, Binda C, Rovida S, Mattevi A, Edmondson DE. FEBS J 278 4860-4869 (2011)
  9. Activity-based probes for studying the activity of flavin-dependent oxidases and for the protein target profiling of monoamine oxidase inhibitors. Krysiak JM, Kreuzer J, Macheroux P, Hermetter A, Sieber SA, Breinbauer R. Angew Chem Int Ed Engl 51 7035-7040 (2012)
  10. Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC). Vlok N, Malan SF, Castagnoli N, Bergh JJ, Petzer JP. Bioorg Med Chem 14 3512-3521 (2006)
  11. Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors. Chimenti F, Bolasco A, Secci D, Chimenti P, Granese A, Carradori S, Yáñez M, Orallo F, Ortuso F, Alcaro S. Bioorg Med Chem 18 5715-5723 (2010)
  12. On the formation and nature of the imidazoline I2 binding site on human monoamine oxidase-B. McDonald GR, Olivieri A, Ramsay RR, Holt A. Pharmacol Res 62 475-488 (2010)
  13. Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives. Chimenti F, Carradori S, Secci D, Bolasco A, Bizzarri B, Chimenti P, Granese A, Yáñez M, Orallo F. Eur J Med Chem 45 800-804 (2010)
  14. Functional identification of two novel genes from Pseudomonas sp. strain HZN6 involved in the catabolism of nicotine. Qiu J, Ma Y, Wen Y, Chen L, Wu L, Liu W. Appl Environ Microbiol 78 2154-2160 (2012)
  15. Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds. Toprakçí M, Yelekçi K. Bioorg Med Chem Lett 15 4438-4446 (2005)
  16. The structure of monoamine oxidase from Aspergillus niger provides a molecular context for improvements in activity obtained by directed evolution. Atkin KE, Reiss R, Koehler V, Bailey KR, Hart S, Turkenburg JP, Turner NJ, Brzozowski AM, Grogan G. J Mol Biol 384 1218-1231 (2008)
  17. Indanones as high-potency reversible inhibitors of monoamine oxidase. Mostert S, Petzer A, Petzer JP. ChemMedChem 10 862-873 (2015)
  18. A synchronized substrate-gating mechanism revealed by cubic-core structure of the bovine branched-chain alpha-ketoacid dehydrogenase complex. Kato M, Wynn RM, Chuang JL, Brautigam CA, Custorio M, Chuang DT. EMBO J 25 5983-5994 (2006)
  19. Inhibition of monoamine oxidase by selected C5- and C6-substituted isatin analogues. Manley-King CI, Bergh JJ, Petzer JP. Bioorg Med Chem 19 261-274 (2011)
  20. 8-Substituted 3-arylcoumarins as potent and selective MAO-B inhibitors: synthesis, pharmacological evaluation, and docking studies. Viña D, Matos MJ, Ferino G, Cadoni E, Laguna R, Borges F, Uriarte E, Santana L. ChemMedChem 7 464-470 (2012)
  21. Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Chimenti F, Secci D, Bolasco A, Chimenti P, Granese A, Carradori S, Maccioni E, Cardia MC, Yáñez M, Orallo F, Alcaro S, Ortuso F, Cirilli R, Ferretti R, Distinto S, Kirchmair J, Langer T. Bioorg Med Chem 18 5063-5070 (2010)
  22. MAO enzymes inhibitory activity of new benzimidazole derivatives including hydrazone and propargyl side chains. Can ÖD, Osmaniye D, Demir Özkay Ü, Sağlık BN, Levent S, Ilgın S, Baysal M, Özkay Y, Kaplancıklı ZA. Eur J Med Chem 131 92-106 (2017)
  23. What a Difference a Methyl Group Makes: The Selectivity of Monoamine Oxidase B Towards Histamine and N-Methylhistamine. Maršavelski A, Vianello R. Chemistry 23 2915-2925 (2017)
  24. The relationship between enhanced enzyme activity and structural dynamics in ionic liquids: a combined computational and experimental study. Kim HS, Ha SH, Sethaphong L, Koo YM, Yingling YG. Phys Chem Chem Phys 16 2944-2953 (2014)
  25. Discovery of 3-Hydroxy-3-phenacyloxindole Analogues of Isatin as Potential Monoamine Oxidase Inhibitors. Tripathi RK, Krishnamurthy S, Ayyannan SR. ChemMedChem 11 119-132 (2016)
  26. An improved approach to steady-state analysis of monoamine oxidases. Ramsay RR, Olivieri A, Holt A. J Neural Transm (Vienna) 118 1003-1019 (2011)
  27. Design, synthesis, in vitro MAO-B inhibitory evaluation, and computational studies of some 6-nitrobenzothiazole-derived semicarbazones. Tripathi RK, Goshain O, Ayyannan SR. ChemMedChem 8 462-474 (2013)
  28. Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors. Gökhan-Kelekçi N, Simşek OO, Ercan A, Yelekçi K, Sahin ZS, Işik S, Uçar G, Bilgin AA. Bioorg Med Chem 17 6761-6772 (2009)
  29. Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites and estimation of inhibitors thermodynamic properties. Yelekçi K, Karahan O, Toprakçi M. J Neural Transm (Vienna) 114 725-732 (2007)
  30. Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Van der Walt EM, Milczek EM, Malan SF, Edmondson DE, Castagnoli N, Bergh JJ, Petzer JP. Bioorg Med Chem Lett 19 2509-2513 (2009)
  31. Inhibition of monoamine oxidase by C5-substituted phthalimide analogues. Manley-King CI, Bergh JJ, Petzer JP. Bioorg Med Chem 19 4829-4840 (2011)
  32. New insights into the structures and functions of human monoamine oxidases A and B. Edmondson DE, DeColibus L, Binda C, Li M, Mattevi A. J Neural Transm (Vienna) 114 703-705 (2007)
  33. Synthesis of some novel hydrazone and 2-pyrazoline derivatives: monoamine oxidase inhibitory activities and docking studies. Evranos-Aksöz B, Yabanoğlu-Çiftçi S, Uçar G, Yelekçi K, Ertan R. Bioorg Med Chem Lett 24 3278-3284 (2014)
  34. A rational approach to elucidate human monoamine oxidase molecular selectivity. Mangiatordi GF, Alberga D, Pisani L, Gadaleta D, Trisciuzzi D, Farina R, Carotti A, Lattanzi G, Catto M, Nicolotti O. Eur J Pharm Sci 101 90-99 (2017)
  35. Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives. Sakane C, Okitsu T, Wada A, Sagami H, Shidoji Y. Biochem Biophys Res Commun 444 24-29 (2014)
  36. Synthesis of New Hydrazone Derivatives for MAO Enzymes Inhibitory Activity. Can NÖ, Osmaniye D, Levent S, Sağlık BN, İnci B, Ilgın S, Özkay Y, Kaplancıklı ZA. Molecules 22 E1381 (2017)
  37. Kinetic properties of recombinant MAO-A on incorporation into phospholipid nanodisks. Cruz F, Edmondson DE. J Neural Transm (Vienna) 114 699-702 (2007)
  38. Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera diffusa (Damiana). Chaurasiya ND, Zhao J, Pandey P, Doerksen RJ, Muhammad I, Tekwani BL. Molecules 24 E810 (2019)
  39. Synthesis and molecular modelling of novel substituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase-A inhibitors. Chimenti F, Bolasco A, Manna F, Secci D, Chimenti P, Granese A, Befani O, Turini P, Alcaro S, Ortuso F. Chem Biol Drug Des 67 206-214 (2006)
  40. Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of N,N'-bis[2-oxo-2H-benzopyran]-3-carboxamides. Chimenti F, Secci D, Bolasco A, Chimenti P, Granese A, Carradori S, Befani O, Turini P, Alcaro S, Ortuso F. Bioorg Med Chem Lett 16 4135-4140 (2006)
  41. Drug design, synthesis, in vitro and in silico evaluation of selective monoaminoxidase B inhibitors based on 3-acetyl-2-dichlorophenyl-5-aryl-2,3-dihydro-1,3,4-oxadiazole chemical scaffold. Distinto S, Meleddu R, Yanez M, Cirilli R, Bianco G, Sanna ML, Arridu A, Cossu P, Cottiglia F, Faggi C, Ortuso F, Alcaro S, Maccioni E. Eur J Med Chem 108 542-552 (2016)
  42. New coumarin derivatives: design, synthesis and use as inhibitors of hMAO. He X, Chen YY, Shi JB, Tang WJ, Pan ZX, Dong ZQ, Song BA, Li J, Liu XH. Bioorg Med Chem 22 3732-3738 (2014)
  43. Structure-activity relationships in the inhibition of monoamine oxidase B by 1-methyl-3-phenylpyrroles. Ogunrombi MO, Malan SF, Terre'blanche G, Castagnoli N, Bergh JJ, Petzer JP. Bioorg Med Chem 16 2463-2472 (2008)
  44. Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. La Regina G, Silvestri R, Gatti V, Lavecchia A, Novellino E, Befani O, Turini P, Agostinelli E. Bioorg Med Chem 16 9729-9740 (2008)
  45. Catalytic and inhibitor binding properties of zebrafish monoamine oxidase (zMAO): comparisons with human MAO A and MAO B. Aldeco M, Arslan BK, Edmondson DE. Comp Biochem Physiol B Biochem Mol Biol 159 78-83 (2011)
  46. High-level expression and purification of rat monoamine oxidase A (MAO A) in Pichia pastoris: comparison with human MAO A. Wang J, Edmondson DE. Protein Expr Purif 70 211-217 (2010)
  47. Insight into the functional and structural properties of 3-arylcoumarin as an interesting scaffold in monoamine oxidase B inhibition. Matos MJ, Vilar S, García-Morales V, Tatonetti NP, Uriarte E, Santana L, Viña D. ChemMedChem 9 1488-1500 (2014)
  48. Isatin inhibits SH-SY5Y neuroblastoma cell invasion and metastasis through MAO/HIF-1α/CXCR4 signaling. Sun W, Zhang L, Hou L, Ju C, Zhao S, Wei Y. Anticancer Drugs 28 645-653 (2017)
  49. Development of spin-labeled pargyline analogues as specific inhibitors of human monoamine oxidases A and B. Upadhyay AK, Edmondson DE. Biochemistry 48 3928-3935 (2009)
  50. Thio- and aminocaffeine analogues as inhibitors of human monoamine oxidase. Booysen HP, Moraal C, Terre'Blanche G, Petzer A, Bergh JJ, Petzer JP. Bioorg Med Chem 19 7507-7518 (2011)
  51. 8-Aryl- and alkyloxycaffeine analogues as inhibitors of monoamine oxidase. Strydom B, Bergh JJ, Petzer JP. Eur J Med Chem 46 3474-3485 (2011)
  52. Evaluation of Natural and Synthetic 1,4-naphthoquinones as Inhibitors of Monoamine Oxidase. Mostert S, Petzer A, Petzer JP. Chem Biol Drug Des 87 737-746 (2016)
  53. Recognition dynamics of dopamine to human Monoamine oxidase B: role of Leu171/Gln206 and conserved water molecules in the active site cavity. Dasgupta S, Mukherjee S, Mukhopadhyay BP, Banerjee A, Mishra DK. J Biomol Struct Dyn 36 1439-1462 (2018)
  54. Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques. Rojas RJ, Edmondson DE, Almos T, Scott R, Massari ME. Bioorg Med Chem 23 770-778 (2015)
  55. Azure B and a synthetic structural analogue of methylene blue, ethylthioninium chloride, present with antidepressant-like properties. Delport A, Harvey BH, Petzer A, Petzer JP. Life Sci 117 56-66 (2014)
  56. Characterization of detergent purified recombinant rat liver monoamine oxidase B expressed in Pichia pastoris. Upadhyay AK, Edmondson DE. Protein Expr Purif 59 349-356 (2008)
  57. Molecular docking of inhibitors into monoamine oxidase B. Harkcom WT, Bevan DR. Biochem Biophys Res Commun 360 401-406 (2007)
  58. The effects of buffer cations on interactions between mammalian copper-containing amine oxidases and their substrates. Holt A, Degenhardt OS, Berry PD, Kapty JS, Mithani S, Smith DJ, Di Paolo ML. J Neural Transm (Vienna) 114 733-741 (2007)
  59. A Strategy to Employ Clitoria ternatea as a Prospective Brain Drug Confronting Monoamine Oxidase (MAO) Against Neurodegenerative Diseases and Depression. Margret AA, Begum TN, Parthasarathy S, Suvaithenamudhan S. Nat Prod Bioprospect 5 293-306 (2015)
  60. Hepatic monoamine oxidase B is involved in endogenous geranylgeranoic acid synthesis in mammalian liver cells. Tabata Y, Shidoji Y. J Lipid Res 61 778-789 (2020)
  61. Monoamine oxidase inhibition by C4-substituted phthalonitriles. Manley-King CI, Bergh JJ, Petzer JP. Bioorg Chem 40 114-124 (2012)
  62. Up-regulated monoamine oxidase in the mouse uterus during the peri-implantation period. Zhang D, Lei C, Zhang W. Arch Gynecol Obstet 284 861-866 (2011)
  63. Virtual screening and drug repurposing experiments to identify potential novel selective MAO-B inhibitors for Parkinson's disease treatment. Crisan L, Istrate D, Bora A, Pacureanu L. Mol Divers 25 1775-1794 (2021)
  64. 4-Organoseleno-Isoquinolines Selectively and Reversibly Inhibit the Cerebral Monoamine Oxidase B Activity. Sampaio TB, Da Rocha JT, Prigol M, Saraiva RA, Nogara PF, Stein AL, da Rocha JB, Zeni G, Nogueira CW. J Mol Neurosci 59 135-145 (2016)
  65. Inhibition of monoamine oxidase by selected phenylalkylcaffeine analogues. Petzer A, Grobler P, Bergh JJ, Petzer JP. J Pharm Pharmacol 66 677-687 (2014)
  66. Marine natural products with monoamine oxidase (MAO) inhibitory activity. Hong A, Tu LC, Yang I, Lim KM, Nam SJ. Pharm Biol 58 716-720 (2020)
  67. Mutagenic probes of the role of Ser209 on the cavity shaping loop of human monoamine oxidase A. Wang J, Harris J, Mousseau DD, Edmondson DE. FEBS J 276 4569-4581 (2009)
  68. Navigating into the Chemical Space of Monoamine Oxidase Inhibitors by Artificial Intelligence and Cheminformatics Approach. Kumar S, Nair AS, Bhashkar V, Sudevan ST, Koyiparambath VP, Khames A, Abdelgawad MA, Mathew B. ACS Omega 6 23399-23411 (2021)
  69. Novel Thiosemicarbazone Derivatives: In Vitro and In Silico Evaluation as Potential MAO-B Inhibitors. Osmaniye D, Kurban B, Sağlık BN, Levent S, Özkay Y, Kaplancıklı ZA. Molecules 26 6640 (2021)
  70. Profiling substrate specificity of two series of phenethylamine analogs at monoamine oxidase A and B. Heuson E, Storgaard M, Huynh TH, Charmantray F, Gefflaut T, Bunch L. Org Biomol Chem 12 8689-8695 (2014)
  71. Promising Non-cytotoxic Monosubstituted Chalcones to Target Monoamine Oxidase-B. Iacovino LG, Pinzi L, Facchetti G, Bortolini B, Christodoulou MS, Binda C, Rastelli G, Rimoldi I, Passarella D, Di Paolo ML, Dalla Via L. ACS Med Chem Lett 12 1151-1158 (2021)
  72. Species differences in the selective inhibition of monoamine oxidase (1-methyl-2-phenylethyl)hydrazine and its potentiation by cyanide. Ramadan ZB, Wrang ML, Tipton KF. Neurochem Res 32 1783-1790 (2007)
  73. Natural based piperine derivatives as potent monoamine oxidase inhibitors: an in silico ADMET analysis and molecular docking studies. Dhiman P, Malik N, Khatkar A. BMC Chem 14 12 (2020)
  74. Why p-OMe- and p-Cl-β-Methylphenethylamines Display Distinct Activities upon MAO-B Binding. Fierro A, Edmondson DE, Celis-Barros C, Rebolledo-Fuentes M, Zapata-Torres G. PLoS One 11 e0154989 (2016)
  75. Synthesis and Biological Evaluation of New Thiosemicarbazone Derivative Schiff Bases as Monoamine Oxidase Inhibitory Agents. Çavuşoğlu BK, Sağlık BN, Osmaniye D, Levent S, Acar Çevik U, Karaduman AB, Özkay Y, Kaplancıklı ZA. Molecules 23 E60 (2017)
  76. 5-Demethoxy-10'-ethoxyexotimarin F, a New Coumarin with MAO-B Inhibitory Potential from Murraya exotica L. Xia-Hou ZR, Feng XF, Mei YF, Zhang YY, Yang T, Pan J, Yang JH, Wang YS. Molecules 27 4950 (2022)
  77. From Monoamine Oxidase Inhibition to Antiproliferative Activity: New Biological Perspectives for Polyamine Analogs. Nordio G, Piazzola F, Cozza G, Rossetto M, Cervelli M, Minarini A, Basagni F, Tassinari E, Dalla Via L, Milelli A, Di Paolo ML. Molecules 28 6329 (2023)
  78. Isatin-based benzyloxybenzene derivatives as monoamine oxidase inhibitors with neuroprotective effect targeting neurogenerative disease treatment. Benny F, Oh JM, Kumar S, Abdelgawad MA, Ghoneim MM, Abdel-Bakky MS, Kukerti N, Jose J, Kim H, Mathew B. RSC Adv 13 35240-35250 (2023)
  79. Synthesis and evaluation of human monoamine oxidase inhibitory activities of some 3,5-diaryl-N-substituted-4,5-dihydro-1H-pyrazole-1-carbothioamide derivatives. Sentürk K, Tan OU, Ciftçi SY, Uçar G, Palaska E. Arch Pharm (Weinheim) 345 695-702 (2012)


Quick links